Edoxaban 12 months superior to 3 months for VTE prevention in cancer DVT, regardless of anemia status
For cancer patients with a leg blood clot and anemia, does longer treatment work better?
In this prespecified subgroup analysis of the ONCO DVT study, 12 months of edoxaban was superior to 3 months for preventing symptomatic recu…
Cancer patients with leg clots and anemia get better protection against new clots with 12 months of edoxaban compared to just 3 months, with…
pCR shows poor surrogacy for OS in neoadjuvant GEA trials overall, but strong for esophageal adenocarcinoma
When a cancer disappears before surgery, does it mean patients live longer? Not always, a major review finds
A meta-analysis of 26 RCTs (n=7452) found pathologic complete response (pCR) was not a valid surrogate for overall survival (OS) in neoadjuv…
For stomach or esophageal cancer, a tumor disappearing before surgery does not always mean patients live longer, a major review finds.
PD-1 inhibitors + chemo improve OS, PFS, ORR in first-line advanced ESCC; benefit limited in PD-L1 CPS <1
Who benefits most from new esophageal cancer treatment? Most patients do, except one group
A meta-analysis of 8 RCTs (n=4702) found first-line PD-1 inhibitors plus chemotherapy significantly improved OS (HR=0.68, 95% CI: 0.63-0.74;…
For most advanced esophageal cancer patients, adding immunotherapy to chemotherapy extends life and shrinks tumors, but those with low PD-L1…
Induction Nivolumab Before CRT Misses Feasibility Threshold in High-Risk HPV+ OPC
Can a new approach reduce relapse in high-risk throat cancer? Early results show promise but raise safety concerns
In a phase II RCT of high-risk HPV-positive oropharyngeal cancer patients, induction nivolumab before chemoradiation did not meet the predef…
Adding immunotherapy before standard treatment reduced cancer relapse in high-risk throat cancer patients, though severe side effects preven…
Camizestrant 75 mg achieves maximal ER reduction in 5-7 days, well-tolerated in SERENA-3 WOO trial
Can a new breast cancer drug work in just days? Study shows it quickly reduces tumor fuel and slows growth
In the presurgical SERENA-3 trial, camizestrant reduced ER expression by ~65% across all doses (75, 150, 300 mg) by 5-7 days in postmenopaus…
A new breast cancer drug cuts tumor fuel by 65% in just five to seven days and slows growth with minimal side effects at the lowest dose.
AI tool predicts acute leukemia subtypes with AUROC 0.94 for AML, 0.98 for promyelocytic, 0.84 for ALL in international cohort
Can a simple blood test help diagnose leukemia? An AI tool shows promise but still needs work
An AI tool was tested on a retrospective, international cohort of 6206 leukemia patients from 20 centers to predict acute leukemia subtypes …
An AI tool can spot leukemia from standard blood tests but must refuse to guess for most patients until doctors refine it to help more peopl…
Home treatment for low-risk cancer-associated PE shows 4.6% major bleeding rate in ONCO PE companion report
Could some cancer patients safely treat blood clots at home? New research suggests yes
A predetermined companion report from the ONCO PE trial evaluated 3-month outcomes for home vs.
Active cancer patients with low-risk lung clots can safely take blood thinners at home, avoiding disruptive hospital stays while staying on …
Axitinib + Octreotide Shows PFS Benefit in Extrapancreatic NETs per Central Review (HR 0.71)
Can a blood vessel blocker help slow rare gut tumors? Study shows mixed results for new combination treatment
In the AXINET phase II/III trial, axitinib plus octreotide LAR significantly improved median PFS per blinded independent central review (16.…
A new blood vessel blocker combined with standard hormone shots helped rare gut tumors shrink and delayed growth longer than placebo, despit…
Bibliometric analysis maps 4.3-fold rise in elderly glioma research, highlights MGMT focus
Why is brain tumor research for older adults lagging behind? A new analysis reveals a critical gap
A bibliometric analysis of 1,299 publications found a 4.3-fold increase in research on elderly glioma from 2001 to 2025, with the U.S., Ital…
Glioma research for older adults lags behind because studies focus on younger patients, leaving a critical gap in treating aggressive tumors…
Exercise during adjuvant chemo reduces fatigue, depression in CRC patients
Can exercise help during colon cancer treatment? A review finds it may ease fatigue and depression
A meta-analysis of 9 studies found exercise interventions during adjuvant chemotherapy for colorectal cancer significantly reduced fatigue (…
For colorectal cancer patients on chemotherapy, adding exercise to treatment significantly reduces crushing fatigue and lowers depression.
VATS lobectomy improves overall survival vs open surgery in early-stage NSCLC
Does a less invasive lung cancer surgery help people live longer? New analysis says yes
An individual patient data meta-analysis of 3 RCTs (n=1185) found VATS lobectomy for early-stage NSCLC was associated with a 21% mortality r…
A new analysis of nearly 1,200 patients shows less invasive lung surgery lowers the risk of death by 21% compared to traditional open surger…
Home-based prehabilitation improves preoperative 6MWT in colorectal cancer surgery but benefits not sustained
Can home workouts before colon cancer surgery help? They boost fitness before the operation, but not after
A meta-analysis found home-based multimodal prehabilitation significantly improved preoperative 6-minute walk test performance (MD=40.61, 95…
Home workouts before colon cancer surgery boost fitness right before the operation, but those gains fade within weeks and don't lower compli…